ALVOCIDIB
Alvocidib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against cyclin-dependent kinase 2 and cyclin-dependent kinase 4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
65 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 14 | 12 | — | — | — | 23 |
| Neoplasms | D009369 | — | C80 | 19 | 1 | — | — | 1 | 21 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 8 | 8 | — | — | — | 14 |
| Myeloid leukemia | D007951 | — | C92 | 8 | 8 | — | — | — | 14 |
| Lymphoma | D008223 | — | C85.9 | 10 | 5 | — | — | — | 12 |
| Lymphoid leukemia | D007945 | — | C91 | 8 | 5 | — | — | — | 11 |
| Recurrence | D012008 | — | — | 8 | 4 | — | — | — | 10 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 6 | 5 | — | — | — | 9 |
| Mantle-cell lymphoma | D020522 | — | — | 4 | 4 | — | — | — | 6 |
| Monocytic leukemia acute | D007948 | — | — | 2 | 4 | — | — | — | 6 |
Show 50 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anemia | D000740 | HP_0001903 | D64.9 | 2 | — | — | — | — | 2 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 2 | — | — | — | — | 2 |
| Myeloid leukemia chronic-phase | D015466 | — | — | 2 | — | — | — | — | 2 |
| Blast crisis | D001752 | — | — | 2 | — | — | — | — | 2 |
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | 1 | — | — | — | — | 1 |
| Male breast neoplasms | D018567 | — | — | 1 | — | — | — | — | 1 |
| Refractory anemia with excess of blasts | D000754 | — | D46.2 | 1 | — | — | — | — | 1 |
| Refractory anemia | D000753 | — | — | 1 | — | — | — | — | 1 |
| Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | 1 | — | — | — | — | 1 |
| Hairy cell leukemia | D007943 | — | C91.4 | 1 | — | — | — | — | 1 |
Show 21 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ALVOCIDIB |
| INN | alvocidib |
| Description | Alvocidib is a synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation. It has a role as an antineoplastic agent, an EC 2.7.11.22 (cyclin-dependent kinase) inhibitor, an antirheumatic drug and an apoptosis inducer. It is a dihydroxyflavone, a hydroxypiperidine, a member of monochlorobenzenes and a tertiary amino compound. It is a conjugate base of an alvocidib(1+). |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1 |
Identifiers
| PDB | — |
| CAS-ID | 146426-40-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL428690 |
| ChEBI ID | — |
| PubChem CID | 5287969 |
| DrugBank | DB03496 |
| UNII ID | 45AD6X575G (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CCNT1
CCNT1
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,196 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
72 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use